<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1065">
  <stage>Registered</stage>
  <submitdate>3/02/2006</submitdate>
  <approvaldate>7/02/2006</approvaldate>
  <actrnumber>ACTRN12606000053527</actrnumber>
  <trial_identification>
    <studytitle>Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with Cystic Fibrosis.</studytitle>
    <scientifictitle>Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four times daily to people with Cystic Fibrosis.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>X05-0185</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Human genetics and inherited disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>4mL of 6% saline delivered via an eFlow nebuliser four times daily for 2 weeks.</interventions>
    <comparator>4mL of 6% saline delivered via an eFlow nebuliser twice daily for 2 weeks</comparator>
    <control>Dose comparison</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Tolerance of the prescribed regimen of inhalation</outcome>
      <timepoint>Assessed at the end of the 2-week inhalation period</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Lung function</outcome>
      <timepoint>Measured at baseline and at the end of the 2-week inhalation period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Oxyhaemoglobin saturation</outcome>
      <timepoint>Measured at baseline and at the end of the 2-week inhalation period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Symptom severity on a visual analogue scale</outcome>
      <timepoint>Measured at baseline and at the end of the 2-week inhalation period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life scores</outcome>
      <timepoint>Measured at baseline and at the end of the 2-week inhalation period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cytokine concentration</outcome>
      <timepoint>Measured at baseline and at the end of the 2-week inhalation period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bacterial load.</outcome>
      <timepoint>Measured at baseline and at the end of the 2-week inhalation period.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cystic fibrosis, member of RPA Hospital CF Clinic, stable clinical condition (no non-routine antibiotics in the previous 2 weeks), FEV1 &gt;40% pred.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unable/unwilling to provide informed consent, major haemoptysis in the previous year, pregnant or lactating, investigational drugs in the previous 30 days. There is no age limit.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>computer-generated random number list, with stratification for:(i) routine rhDNase use; Y/N(ii) FEV1 &gt; 50% predicted on admission; Y/N(iii) routine HS use; Y/N(iv) presence of an epidemic P.aeruginosa pulsotype; Y/N(v) use of physiotherapy at least 5 / week; Y/N.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>10/02/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Sydney South West Area Health Service</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>US CF Foundation</fundingname>
      <fundingaddress />
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service Ethics Review Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mr Mark Elkins</name>
      <address>Department of Respiratory Medicine
Royal Rpince Alfred Hospital 
Level 11
E Block
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95158712</phone>
      <fax>+61 2 95158196</fax>
      <email>elkinsm@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sarah Newton-John</name>
      <address>Woolcock Institue of Research
PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>sarahnj@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>